文献速递临床试验与 GCP流行病学与生物统计

个性化随机对照试验:一种新试验设计的评价

The Personalised Randomized Controlled Trial: Evaluation of a new trial design.
PubMed 文献 · Stat Med · 2023-02-02

针对多种常见治疗存在不确定性但传统多臂随机试验不可行的临床场景,提出个性化随机对照试验设计,使每名参与者在其适用的「个性化随机化列表」内随机分配。采用模拟评估包括类网状Meta分析在内的多种新分析方法,结论为汇总不同参与者类型的数据可行,所提方法在估计偏倚与覆盖度方面表现良好,可给出精度合理的总体治疗排名,若用于指导干预政策与个体临床决策,平均可能改善结局。

要点

  • 个性化随机对照试验让每名参与者在适合自己的治疗列表内随机,主要目标是产生治疗排名而非相对效应估计。
  • 模拟评估显示类网状Meta分析可汇总不同参与者类型的数据,对中度亚组-干预交互稳健。
  • 所提方法在估计偏倚与覆盖度方面表现良好,可给出精度合理的总体治疗排名。

核心结论

  • 个性化随机对照试验的分析可通过汇总不同参与者类型的数据进行,对基于模拟参数的中度亚组-干预交互稳健。
  • 所提方法在估计偏倚与覆盖度方面表现良好,可给出精度合理的总体治疗排名,若用于确定干预政策并指导个体临床决策,平均可能改善结局。

研究设计与样本

  • 研究采用模拟方法评估个性化随机对照试验设计的多种新分析方法,并与较少利用间接证据的分析方法进行比较。

主要发现

  • 所提分析中,具有相同个性化随机化列表的参与者视为一项试验,同时利用直接与间接证据。
  • 研究提出新的性能指标,包括若使用试验排名而非随机选择来指导未来治疗时的预期结局改善。
  • 所提方法在估计偏倚与覆盖度方面表现良好,可给出精度合理的总体治疗排名。

临床怎么用

  • 原文结论指出,若将所提方法产生的总体治疗排名用于确定干预政策并指导个体临床决策,平均可能改善结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In some clinical scenarios, for example, severe sepsis caused by extensively drug resistant bacteria, there is uncertainty between many common treatments, but a conventional multiarm randomized trial is not possible because individual participants may not be eligible to receive certain treatments. The Personalised Randomized Controlled Trial design allows each participant to be randomized between a "personalised randomization list" of treatments that are suitable for them. The primary aim is to produce treatment rankings that can guide choice of treatment, rather than focusing on the estimates of relative treatment effects. Here we use simulation to assess several novel analysis approaches for this innovative trial design. One of the approaches is like a network meta-analysis, where participants with the same personalised randomization list are like a trial, and both direct and indirect evidence are used. We evaluate this proposed analysis and compare it with analyses making less use of indirect evidence. We also propose new performance measures including the expected improvement in outcome if the trial's rankings are used to inform future treatment rather than random choice. We conclude that analysis of a personalized randomized controlled trial can be performed by pooling data from different types of participants and is robust to moderate subgroup-by-intervention interactions based on the parameters of our simulation. The proposed approach performs well with respect to estimation bias and coverage. It provides an overall treatment ranking list with reasonable precision, and is likely to improve outcome on average if used to determine intervention policies and guide individual clinical decisions.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Lee KM, Turner RM, Thwaites GE, et al. The Personalised Randomized Controlled Trial: Evaluation of a new trial design. Stat Med. 2023. PMID: 36732886. doi:10.1002/sim.9663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。